Page last updated: 2024-11-12

vaf347

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	10172275
SCHEMBL ID	2946515
MeSH ID	M0497186

Synonyms (15)

Synonym
vaf347 ,
4-(3-chlorophenyl)-n-[4-(trifluoromethyl)phenyl]pyrimidin-2-amine
574759-62-9
2-pyrimidinamine, 4-(3-chlorophenyl)-n-[4-(trifluoromethyl)phenyl]-
SCHEMBL2946515
DTXSID0041149
HY-135750
CS-0113926
SY269555
mfcd17010254
MS-25401
xtkuztbzrijtfr-uhfffaoysa-n
(4-(3-chloro-phenyl)-pyrimidin-2-yl)-(4-trifluoromethyl-phenyl)-amine
AKOS040740511
EX-A7737

Research Excerpts

Overview

VAF347 is a low-molecular-weight compound, which activates the aryl hydrocarbon receptor (AhR) It inhibits allergic lung inflammation in vivo.

Excerpt	Reference	Relevance
"VAF347 is a low-molecular-weight compound, which activates the aryl hydrocarbon receptor (AhR). "	( Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Draghici, E; Gregori, S; Hauben, E; Migliavacca, B; Olivieri, S; Roncarolo, MG; Woisetschläger, M, 2008)	1.79
"VAF347 is a low-molecular-weight compound that inhibits allergic lung inflammation in vivo. "	( Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Denison, MS; Harrer, N; Lawrence, BP; Neruda, W; Novak, H; Reichel, C; Vorderstrasse, BA; Woisetschläger, M, 2008)	1.79

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	17.54 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.56 (4.65)
Search Engine Demand Index	10.37 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (17.54)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Alloxan Diabetes [description not available]	2.31	1
Innate Inflammatory Response [description not available]	2.51	2
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	2.31	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.51	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.03	1
Airway Hyper-Responsiveness [description not available]	2.03	1